Fig. 4.

(A, B) Patients who achieved complete response (CR) with complete disappearance of fluorine-18 deoxyglucose uptake. (C) Patient with peripheral T-cell lymphoma (PTCL) showing partial response (PR) after the second cycle. His remaining target lesions disappeared after the 12th cycle (red dotted line), although new lesions appeared (yellow dotted line). (D, E) Two patients showed progressive disease (PD) after their second cycle of brentuximab vedotin. Their responses differed based on site because several lesions disappeared (red dotted line) while others progressed (yellow dotted line). MUM1, multiple myeloma oncogene 1; ENKTL, extranodal natural killer/T-cell lymphoma. DLBCL, diffuse large B-cell lymphoma.